B01 BLU-667: A highly selective RET inhibitor to target RET-driven NSCLC. Erica Evans, Blueprint Medicines, Cambridge, MA, USA.

B02 Heterogeneity of epithelial-to-mesenchymal transition and resistance mutation in ALK inhibitor-resistant lung cancer and its circumvention. Koji Fukuda, Division of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Ishikawa, Japan.

B03 Suppression of lung adenocarcinoma growth and metastasis by stromal Hedgehog pathway activation. James Kim, University of Texas Southwestern, Dallas, TX, USA.

B04 Changes of PD-L1 expression according to tumor infiltrating lymphocytes in acquired EGFR-TKI resistant EGFR-mutant non-small-cell lung cancer. Sook-hee Hong, College of Medicine, The Catholic University of Korea, Seoul, NA, Republic of Korea.

B05 Hippo effector YAP directly regulates the expression of PD-L1 transcripts in EGFR-TKI-resistant lung adenocarcinoma. Chaeuk Chung, Chungnam national university, Daejeon, Jung gu, South Korea.

B06 Targeted radiopeptide therapy re188-P2045 to treat neuroendocrine lung cancer. Chris Adams, Andarix Pharmaceuticals, Somerville, MA, USA.

B07 Characterization of branched-chain aminotransferase 1 as a novel therapeutic target for small cell lung cancer. Napoleon Butler, University of Virginia, Charlottesville, VA, USA.

B08 Targeting NOTCH activation in small cell lung cancer through LSD1 inhibition. David MacPherson, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.

B09 Evaluating transcription factor networks as targets for the treatment of small cell lung cancer. Karine Pozo, The University of Texas Southwestern Medical Center, Dallas, TX, USA.

B10 Radiomics signatures on the region defined by using multi-window CT to improve detection lung cancer screening. Hong Lu, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.

B11; PR10 Multi-modality imaging of human lung squamous cell carcinoma reveals unique metabolic dependencies that are effectively targeted with metabolic based therapies. David Shackelford, UCLA David Geffen School of Medicine, Los Angeles, CA, USA.
**Poster Session B**
Wednesday, January 10, 2018
5:40 p.m.–7:00 p.m.
Legends 5–6 and Encore

**B12 Centrosome clustering inhibition as a novel strategy to sensitize non-small cell lung cancer to radiation treatment and immunotherapy.** Hailun Wang, Department of Radiation Oncology and Molecular Radiation Sciences, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

**B13 The impact of combined CDK9 inhibition and TRAIL treatment on NSCLC.** Itziar Areso Zubiaur, Centre for Cell Death, Cancer, and Inflammation, Department of Cancer Biology, University College London, London, Greater London, United Kingdom.

**B14; PR06 Investigating ectopic lymphoid aggregates in a genetically engineered mouse model of lung adenocarcinoma.** Kelli Connolly, Yale University, New Haven, CT, USA.

**B15 Increased presence of T follicular helper cells in lung adenocarcinoma is associated with mutational load.** Katey Enfield, British Columbia Cancer Research Centre, Vancouver, BC, Canada.

**B16; PR11 Hyperspectral imaging tools capture the spatial organization of cell subsets within the tumour microenvironment.** Katey Enfield, British Columbia Cancer Research Centre, Vancouver, BC, Canada.

**B17 Interleukin-17 and -22 Expression in Non-Small Cell Lung Cancer.** Rudolf M. Huber, Division of Respiratory Medicine and Thoracic Oncology, Department of Internal Medicine V, Ludwig Maximilian University of Munich and Thoracic Oncology Centre Munich, Munich, Bavaria, Germany.

**B18 Characterization and therapeutic harnessing of TRAIL's pro-tumorigenic and pro-apoptotic functions in cancer.** Antonella Montinaro, UCL, London, United Kingdom.

**B19; PR07 Role of the microbiota in inflammation and lung cancer.** Ana Robles, National Cancer Institute, Bethesda, MD, USA.

**B20 Premalignant lung lesions demonstrate enhanced PD-L1 upregulation in response to interferon-gamma exposure.** Jane Yanagawa, UCLA, Los Angeles, CA, USA.

**B21 Investigating targeted driver mutations and PD-L1 expression for improved therapy of non-small cell lung cancer.** Akram Alwithenani, Dalhousie University, Halifax, NS, Canada.
B22 Exposure of AZD4547 FGFR-TKI to a lung squamous carcinoma cell line induces resistance by small cell lung cancer like transformation associated with ASCL1. Yosuke Amano, The University of Tokyo Hospital, Tokyo, Japan.

B23 Novel epidermal growth factor receptor inhibitors cross the blood-brain barrier and inhibit the growth of metastatic non-small cell lung cancer. Nicholas Cacalano, University of California at Los Angeles, Los Angeles, CA, USA.


B25; PR04 Decoding tumor microenvironment to enhance NSCLC targeted therapy. Haichuan Hu, MGH Cancer Center, Charlestown, MA, US.

B26 Addressing gaps in molecular testing for patients with lung cancer. Jennifer King, Lung Cancer Alliance, Washington, DC, USA.

B27 Osimertinib (AZD9291) is sensitive and bound with affinity to EGFR exon 20 insertion mutant models.. Yusoo Lee, Seoul National University Cancer Research Institute, Seoul, Seoul, Korea, Republic of.

B28 Targeted inhibition of EGFR and glutaminase induces metabolic crisis in EGFR mutant lung cancer. Milica Momcilovic, UCLA, Los Angeles, CA, USA.

B29; PR13 MET Copy Number Gain Is Associated with Gefitinib Resistance in Leptomeningeal Carcinomatosis of EGFR-mutant Lung Cancer. Shigeki Nanjo, University of California, San Francisco, San Francisco, CA, USA.

B30 3-Dimensional organoid model for acquired drug resistance in non-small cell lung cancer. Ameen Salahudeen, Stanford University, Stanford, CA, US.

B31 A protein synthesis switch underlies initial survival of EGFR mutant lung cancer to EGFR inhibitors. Kyung-A Song, Virginia Commonwealth University, Richmond, VA, USA.

B32 RADIANCERE: An Open-label, Non-randomized, Prospective Biomarker Study to Assess Analytic Concordance Between Non-invasive Testing and Tissue Testing for EGFR T790M Mutation Detection in Patients with Non-small Cell Lung Cancer. Hatim Husain, University of California, Moores Cancer Center, La Jolla, San Diego, CA, USA.

B34; PR05 Safety and Activity of the IL-15/sIL-15Rα Complex ALT-803 in Combination with the anti-PD1 mAb Nivolumab in Metastatic Non-Small Cell Lung Cancer. John Wrangle, Medical University of South Carolina, Charleston, SC, USA.

B35 Biomarkers for precision application of prostacyclin lung cancer chemoprevention. Meredith Tennis, University of Colorado Denver, Aurora, CO, USA.


B37; PR03 Dissecting the playbook of cancer: Genomic analysis of 100,000 human tumors reveals elaborate patterns of activation of the RTK-RAS-MAPK pathway. Gerard Manning, Genentech, South San Francisco, CA, USA.